Endoscopy changes its name in the body area to be explored: laryngoscopy (larynx), gastroscopy (stomach), colonoscopy (colon), cystoscopy (bladder), etc.

*For some endoscopies needed to make a small incision, if it is in the abdomen, one speaks of laparoscopy in the chest, thoracoscopy, etc..

*There are cases where the cancer screening practice with general anesthesia requires a large incision to directly view the area. It speaks of scans to open surgery.

The latest in surgery: laser, cold…

Some of the most innovative techniques in cancer surgery are applied to laser surgery, cryosurgery, electrosurgery, Mohs surgery and laparoscopic surgery.

*Laser surgery. The laser is a beam of light energy. In surgery is used for work requiring high accuracy. For example, to vaporize cancer cells in tumors of the cervix, larynx, liver, rectum, or skin (photoablation). It is also often applied in palliative surgery, for example, when a large tumor pressing the trachea or esophagus and cause difficulty breathing or swallowing.

*Cryosurgery. Its purpose is to freeze and destroy cancer cells. It uses liquid nitrogen or a cold rod. This technique is used sometimes to treat precancerous stages as those that occur in the cervix. Under study is its application to other cancers such as prostate.

*Electrosurgery. Used high-frequency electrical currents to destroy cells. It applies to some skin cancers and mouth.

*Mohs Surgery. The surgeon cuts the skin layer appears to be affected by cancer. That skin is examined immediately under a microscope. Then go back to remove some of the surrounding tissue and is re-examined under the microscope. This process is repeated until it is established that there is any abnormal cell.

*Laparoscopic surgery. Small holes are made by introducing the various surgical instruments, including the endoscope. It is used for some forms of cancer, including gastric, colon, ovary or endometrium.

Oncological

Surgery is the oldest treatment for cancer. This applies especially in cases where the tumor is well defined and has not spread to other parts of the body. Thanks to advances in surgical techniques is becoming increasingly feasible to remove the tumor without damaging healthy tissue or vital functions.

Operations with different objectives

Interventions can be made for different purposes:
*Preventive, when tissue is removed is not evil but is likely to become so.
*Diagnostics, to take a tissue sample can then analyze whether or not cancerous.
*Staging, to determine the extent of the disease.
*Healing, to remove the tumor completely. The intervention is often accompanied by other treatments of chemotherapy, radiotherapy or both.
*Reducers, is used to remove only part of the tumor, when you note that their complete removal may cause damage to organs and surrounding areas. The party has not been withdrawn will be treated using tumor after chemotherapy or radiotherapy.

*Palliative to treat complications associated with tumor progression. For example, to relieve a bowel obstruction resulting from cancer in the abdomen.
*Reparative and reconstructive. For example, when performing an operation to put a breast prosthesis after a mastectomy procedure in which you can get to empty a breast affected by a tumor.

For diagnostic purposes

Interventions for diagnostic (or to assess the extent of the tumor) are available a variety of techniques and medical instruments.

*A just cause discomfort to the patient and do not require anesthesia, as puncture-needle aspiration. To extract a sample of the tumor for analysis later. “Disadvantages? The amount of tissue is so small it does not always make an accurate diagnosis.

There is a belief that can help extend the tumor. But it is an unfounded fear because the probability that clicking with the needle can extend the tumor is extremely low.

*The biopsy is one of the most used techniques. It can be done with needles, but are common practice that after performing a small incision. In this case require anesthesia.

Standard treatment options:

1. Small tumors of the perianal skin or anal margin not
involving the anal sphincter may be adequately treated with local resection.

2. All other types of anal canal cancer in stage II complicating
the anal sphincter or are too large for complete local excision external radiation therapy plus chemotherapy.

Chemotherapy with fluorouracil and mitomycin combined with primary radiation therapy appears more effective than radiotherapy alone. The optimal dose of radiation with concurrent chemotherapy is under evaluation.

Selected tumors are also candidates to receive interstitial irradiation.

3. The Radical resection is reserved for the canal cancer
residual or recurrent anal after nonoperative therapy.

4. Alternately, salvage chemotherapy with fluorouracil and
cisplatin combined with a radiation boost may avoid a permanent colostomy in selected patients with small amounts of residual tumor.

CANCER OF THE YEAR – STAGE IIIA
In most cases of anal cancer in stage IIIA presents clinically as stage II and IIIA is determined that the presence of perirectal nodal disease or adjacent organ complication of clinically apparent. Endorectal or endoanal ultrasound may aid in the classification of the stage prior to treatment.

Standard treatment options:

1. Disease treatment as for stage I and II, using radiation therapy plus
chemotherapy.

2. Abdominoperitoneal resection combined with resection of lymph
femoral nodes, inguinal, groin, and iliac, followed by postoperative radiotherapy.

CANCER OF THE YEAR – PHASE IIIB
The presence of inguinal nodes that are complicated with metastatic disease (unilateral or bilateral) is a poor prognostic sign, although it is possible to achieve the cure of the disease at this time. Because of the poor prognosis associated with this stage, patients should be included in clinical trials whenever possible.

Standard treatment options:

Radiotherapy plus chemotherapy (as described for phase II) with surgical resection of residual disease at the primary site (local or abdominoperineal resection) and unilateral or bilateral dissection, both superficial and deep inguinal nodes to the residual or recurrent tumors.

CANCER OF THE YEAR – PHASE IV
Patients who are at this stage should be considered candidates for clinical trials. There is no standard chemotherapy for patients with metastatic disease. Palliation of symptoms caused by the primary lesion is of vital importance.

Standard treatment options:

1. Palliative surgery.

2. Palliative irradiation.

3. Combined chemotherapy and palliative radiotherapy.

4. Clinical trials.

CANCER OF THE YEAR – RECURRENT
Local recurrences after treatment with radiotherapy and chemotherapy or surgery as primary treatment can be controlled through the use of alternative treatment (surgical resection after radiation and vice versa) is being explored in clinical trials using radiotherapy chemotherapy and / or radiosensitizers to improve local control.

Due to the small number of cases, you need more information can be obtained only through the participation of patients in well designed clinical trials to improve the management of anal cancer. Patients with stages II, III and IV should be considered candidates for clinical trials.

HIV and anal cancer
The tolerance exhibited by patients with human immunodeficiency virus (HIV) and anal carcinoma Standard chemoradiation with fluorouracil / mitomycin is not well defined. Patients with CD4 cell counts below 200 before treatment could experience more acute and late toxic effects, so it may be necessary to modify the doses of chemoradiation in this subset of patients.

The designations in PDQ that treatments are “standard” or “under clinical evaluation” are not to be relied upon to determine whether to grant refunds

Standard treatment options:

Surgical resection is used to treat perianal lesions not involving the anal sphincter (the focus of the operation will depend on location of the lesion in the anal canal).

CANCER OF THE YEAR – PHASE I
Anal cancer stage I was formerly treated with abdominoperineal resection. Current therapies in preserving the sphincter include wide local excision of the perianal skin or anal margin for small tumors, or definitive chemoradiation (fluorouracil and mitomycin) for cancers of the anal canal.

Salvage chemoradiation therapy (fluorouracil and cisplatin plus a radiation boost) may avoid permanent colostomy in patients with residual tumor after undergoing initial nonoperative therapy. Radical resection is reserved for patients with incomplete responses or recurrent disease. It is therefore important continuous surveillance with rectal examination every 3 months during first 2 years and endoscopy / biopsy when indicated after completion of therapy for sphincter preservation.

Standard treatment options:

1. Small tumors of the perianal skin or anal margin not
complicate the anal sphincter may be adequately treated with local resection.

2. Other types of anal canal cancer in stage I complicate
anal sphincter or are too large for complete local excision receive external beam radiation therapy with or without chemotherapy.

Chemotherapy with fluorouracil and mitomycin combined with primary radiation therapy appears more effective than radiotherapy alone. The optimal dose of radiation concurrent with chemotherapy is under clinical evaluation.

Selected tumors are also candidates to receive interstitial irradiation.

3. The Radical resection is reserved for the canal cancer
residual or recurrent anal after nonoperative therapy.

4. Alternately, salvage chemotherapy with fluorouracil and
cisplatin combined with radiation boost may avoid permanent colostomy in selected patients with small amounts of a residual tumor following initial nonoperative therapy.

5. The interstitial Iridium-192 after external beam radiation may
convert some patients with residual disease in patients who respond to treatment in a comprehensive manner

Vigor Orbis, Orbis and Orbis Sports Medical Center will participate in research on effects of physical training during treatment cancer.

Although such research non-core part, we are pleased to deliver a contribution. This consists of project management at the research site Orbis Medical Center and conducting intakes, times of measurement and evaluation with the participants. We will keep you informed of the results. The study called PACT (Physical Activity consistently Cancer Treatment) is an initiative of the Comprehensive Cancer Centre Middle Netherlands and Limburg in collaboration with the University Medical Centre Utrecht and Maastricht.

The PACT is a research study on the effects of physical training in the treatment of breast or colon cancer. Physical training is effective in reducing symptoms of fatigue, healthcare consumption and absenteeism and improving health-related quality of life, physical fitness and body composition? This question, the PACT study in a randomized trial to answer. The PACT study, half the participants follow an exercise program. The other half are asked to maintain their normal pattern of movement. The Comprehensive Cancer Centre Middle Netherlands and Limburg, the PACT study developed in collaboration with the UMC Utrecht and Maastricht University. They collaborate with institutions in the region’s central Netherlands and Limburg that offer exercise. ZonMW (Effectiveness, Impact

The Maitake, Mushroom important in traditional Chinese medicine to be dubbed improvement both in treatment of cancer, both in quality of life by improving the biological functions of life.
This fungus is a very food available and commonly used in the world can find here in Italy.

This study, which was published in the British Journal of Urology “is important news to be disseminated, because the Maitake, which surely has no contraindications or side effects, may increase the chances of people who daily fight against cancer bladder and prostate, which scientists of Urology New York Medical College believe it can reduce 75% of these tumors.
I am therefore very much welcome the daily La Stampa, that gives evidence of this important research, and adds that even a spokesman for the Cancer Research Institute English consider it realistic that after the plant fungi can also be a source of potential new drugs useful against cancer.

The truth is that a simple review of studies on cancer and mistletoe appeared in Publiman sample of the great interest and confirms what we have written so far. Citing only some of the studies of recent years has shown we find that response to different types of cancer.

This applies to a 2004 study on breast cancer led by Lin HS is published as Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. This is a prospective multicenter, randomized, open and conducted in three cancer centers in the People’s Republic of China: Beijing, Tianjin and Shenyang. The study was conducted along the guidelines known as Good Clinical Practice (GCP) to obtain data on the efficacy and side effects of mistletoe extract. However, “this study shows it is said in the conclusions-that the adjuvant mistletoe extract can beneficially reduce the side effects of chemotherapy in cancer patients and improve their quality of life.”

Two years later, in October 2006 – Ziegler would release another study on breast cancer entitled Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). And in that case would begin recognizing the role of mistletoe: mistletoe preparations derived as Iscador-can read it-are commonly used in the CAM / anthroposophic for many types of cancer, particularly solid cancers. Well, the study would conclude that the long-term effect on the progression of Iscador in most cases is significant, as well as on overall survival.

“Iscador-stated in the conclusions, showing a clinically relevant effect on breast tumor progression, as measured by overall survival, as well as time to recurrence, lymph node or distant metastasis. In the short term, psychosomatic self-regulation increases significantly lower complementary Iscador therapy than with conventional therapy alone.
The same researchers publish in June 2007 a new investigation, this time on cervical cancer, entitled Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). And in his return to draw conclusions that Iscador appears capable of extending overall survival, this time among patients with cervical cancer. In addition to improving quality of life. The same conclusion would later study on the effects of mistletoe in cancer of the ovary.

And they are only a few samples. Even in cancers considered very difficult to deal with encouraging results have been obtained. In 1996, for example, was published Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial of Buchler MW et al. This was a phase I / II in which we evaluated the effect of an extract of mistletoe (Eurixor) in 16 patients (7 women and 9 men) with histologically verified ductal pancreatic carcinoma. And although the results suggest that mistletoe does not have a significant influence on tumor growth in advanced pancreatic cancers do indicate that “can stabilize the quality of life and therefore help patients maintain their quality of life in the few months remaining in their life. “

We can also find good results against hepatitis C. In a 2005 study led by Dutchman Hattum J. on 21 patients with hepatitis C, the results suggested an effect comparable to treatment glicirrínico: an improvement in liver inflammation and, therefore, possible long-term reduction of complications such as cirrhosis and liver cancer. “Preparations of mistletoe-add-have the advantage of easy administration and low cost.”

THE DOCTOR’S ANGEL SPANISH EXPERIENCE Borruel
We must say, in conclusion, that during the preparation of this report we are in Internet -www.medicina-naturista.net/Congreso_Malaga_2004/Congreso_2004.htm- the paper that a Spanish doctor, Angel Borruel Omenat-member of the Spanish Association of Physicians Naturists, was introduced in Congress Naturist Medicine and Oncology in November 2004 in the Faculty of Medicine of Granada. Fortunately it was easy to locate and more talk. And that brings seventeen years Borruel using in your query Huesca mistletoe in cancer patients. As we would have had knowledge of its effectiveness through Anthroposophical Medicine-of-specialist who is also after doing a course at a clinic-the anthroposophical Lukas Arlesheim Clinik (Switzerland) – specializing in cancer where the mistletoe is fundamental treatment.
Mistletoe-start-telling “is the most widely used oncology product in Germany, including chemotherapeutic drugs of any kind, because it is perfectly compatible with any conventional treatment.
“And after 17 years of use, what can make us overall assessment of its usefulness in treating cancer?
“In cancer, the results are always the mistletoe because it strengthens the immune system and inhibits the oncogenes that stimulate angiogenesis and prevents apoptosis. At the least, improves quality of life of patients: appetite, energy and mood. In my practice of natural medicine see patients of all kinds and I would not be considered statistically valid, but in Germany, where many patients treated with mistletoe, there are studies that clearly is the increase in life expectancy. This is the case Grossarth-Maticek study done in 2002, for example, which examined 10,226 cases of patients with carcinoma of the colon, rectum, stomach, breast and lung. Of these 1668 were treated with Iscador (VAF in Spain) obtaining a longer life expectancy taxed at 40%. And when there was also a level of self-regulation in the patient is cared for, was on a diet, exercised, etc. .- the difference in expected survival reached 56%. As if today is a drug that increases life expectancy by 56% would be opening news in all news programs.
- Also affects the tumor growth mistletoe?
“It seems that in some cases and although the effect is not so much on the tumor cell as the immune system that strengthens it. The presentation of the conference held in Granada presented the case of a 17 year old girl with an astrocytoma of 3 cm with a large cerebral edema. In November 2000 he was given a life expectancy of two months. He had found two years earlier, underwent surgery and chemotherapy was administered but reappeared two years in an area where the surgery was impossible for him to be turned back to the chemo to no avail. The patient, neurologically, increasingly got worse. In November oncologists decided to suspend the chemo did not get to see any results nor gave him hope. Then started treatment with mistletoe .. but not with the VAF is marketed in Spain as in intracranial tumors can raise the blood pressure of spinal fluid. We start with a type of mistletoe called Isorel and no longer sold in Spain so we had to ask for Germany. He applied intravenously in very high doses-we put up to 20 blisters on a drip at a time-and we were changing the dose. The patient began to feel better neurologically. In spring resonance image was like in the fall but was much better neurologically. To the extent that at the end of course could participate in the concert at the conservatory. He had to give up music for their neurological problems. In the fall the tumor had already been halved and edema to a fourth or a fifth. Today the tumor is still there. Just talked to his mother last week and the oncologist had told him that the tumor was slightly better but still present. In short, we reduce the tumor and edema getting the patient to lead a completely normal life. Today is still clicking but now under the skin. Of course, other patients with astrocytoma have not been so lucky.
“Among other reasons, we assume, because when patients come to you with the disease are already at an advanced stage …
“It’s true. The vast majority get very damaged. Almost never do the first diagnosis. I already come with whatever reports were made.
“And in the cases that have come sooner, what was the outcome?
“Right now I have a patient who began treatment in early December. I was the first he saw her as a doctor. I recommended myself to go to Social Security because it had a huge tumor in her right breast but while waiting to be made all the tests I tried with mistletoe, ozone therapy at high doses, Papimi-joined this device to my office after learning to fund their chances in the last congress organized DSALUD Discovery, changed his diet, I take flax oil in large quantity and recommended antifungal therapy. The right breast tumor was reduced by 10% in little over a month and a half. Indeed, from early January to late February infiltration of the left breast tumor has completely disappeared. Just today (meaning the day we had the conversation that the reader is reading) has seen an oncologist and has said he wants to continue with the treatment of mistletoe. With the tests complete the proposed chemotherapy treatment but for now she prefers to stick with the mistletoe. We do not know where to get. One must be cautious in this. I normally try to terminally ill cancer patients with mistletoe and precancerous. Although all cases of cervical cancer that I have tried, some even in grade three, they have to negative. Always with subcutaneous injection because the oral route is much less effective. My advice also is to follow the lifelong treatment but with different dose and timing.
“What you normally do then is to complement conventional treatments …
“Yes. For example, it is common for patients who have come chemo scheduled, a drip of chemo every three weeks, but can not complete the cycle as a result of side effects, anemia, leukopenia … and thus have four weeks to distance. Then begin with the mistletoe and almost always recover the hematological level. Not until a normal level but to a level enough to get chemo every three weeks. The mistletoe is perfectly complementary with the chemo because adequate doses have no side effects.
-In your experience, is there some kind of tumor more susceptible to improvement treated with mistletoe?
“Except for lung cancer Small cell leukemia cases and all others are susceptible of improvement with the mistletoe. Both a hepatocellular adenoma and prostate cancer, an ovarian tumor as a breast or colon. In the worst response is achieved at least there is improvement in quality of life. But I never do alone. Additionally use mistletoe other therapeutic tools I mentioned before so you never know for sure what degree of improvement corresponds to each part of the treatment but I can tell you that mistletoe I put in a tumor ever. All patients with tumors that have tried for 17 years I have treated with mistletoe.
- Is also effective in the case of metastases?
“In my paper I presented another case, a woman with metastatic hypernephroma hip, lung metastases and another possible impairment. He had said only: “Go home and use pain medications as needed. When we started treatment with VAF Mali had enough pain in the hip. However, the third injection, is usually not as fast, “he began feeling better and hip pain disappeared soon after. Six months after the lung metastases had disappeared and the liver can form a tumor that was said was treatable intractable so just undergoing surgery and conventional treatment. The paradox here is that the patient ended up leaving with mistletoe treatment recommended by his oncologist.
“Being the most widely used oncology product in Germany, what attributes the ignorance that oncologists in Spain seem to have of him?
“I think that oncologists know it all but neither recommend it nor use it. Here we encountered the power of multinationals. I put my hand in the fire for the efficacy of mistletoe to improve the quality of life and survival. Sometimes even by healing the sick. But I fear that oncologists will receive information from the drug multinationals so skewed that they do not conceive it possible to achieve these results with the mistletoe. I’m not saying they have ill will. I believe as a physician that the vast majority of my colleagues want to cure their patients but clearly they are driven by information, at least, wrong. The first patient I treated was 17 years ago a young man of 30 years with adenocarcinoma of the pancreas with metastases in liver and lung. I talked to his oncologist because the family asked me and he said they were going to give palliative chemotherapy without any hope, just to see if they could prolong her life. We begin with the mistletoe and first disappeared lung and liver metastases. It was only with the primary tumor and that was removed surgically. That man is still alive. I do not know how much of his survival was the mistletoe. And I know because I was also getting chemo but given the expectations that had given it seems to me that the role of mistletoe was significant.
“Neither seem to be widely used mistletoe among naturopathic doctors …
“No, do not use it much, unfortunately. Whenever I get together with a colleague at conferences or courses will talk about the results of mistletoe in cancer because I am convinced how well it goes. At the least, improves quality of life for what the patient and patients are grateful. I think Weleda, Swiss drugmaker manufacturer does not make a good media campaign and training among doctors prone to natural medicine.
“One last question: treatment with mistletoe should always be in control of a professiona.

Surgery

The main strategy for curative treatment of cancer is excision of all malignant cells by surgical intervention. In the past, this involved the excision of all affected tissue and as many potentially affected tissue, including the surrounding tissues and lymph nodes. For some tumors, particularly breast cancer, is not accurate as ablative surgery (mastectomy) in most cases.

Improvements in surgical techniques, knowledge in physiology, anesthesia and the availability of powerful antibiotics and blood products, have resulted in more limited surgery, with fewer sequels and more speedy recovery.

However, many cancers are not widespread in the time of diagnosis to curative surgery possible. If the local extent of tumor that affects surrounding tissues can not be resected, or if there are distant metastases, surgery is not curative treatment.

However, it may be beneficial for symptom relief in certain situations such as obstruction, or may have in order to reduce the tumor mass to allow better response to chemotherapy or radiation therapy treatment thereafter.

Radiation

Ionizing radiation can be electromagnetic or particulate matter and produce tissue destruction. Electromagnetic radiation includes gamma rays, a form of radioactive emission, and X-rays, which occur when an electron beam strikes a heavy metal. The particle radiation include electron beams, protons, neutrons, alpha particles (helium nuclei) and pions.

The sensitivity of tumors to radiation is highly variable. Sensitive tumors are those whose sensitivity is higher than the adjacent normal tissue. When such tumors are well-accessible surface tumors or tumors in organs like the uterus which can introduce a source of radiation, can be cured by radiotherapy. The property of radiation to comply to some extent the normal tissue allows treatment of tumors in locations where surgery is not possible by the proximity of vital tissues or because the tumor has begun to infiltrate adjacent structures that can not be sacrificed. Radiation therapy is commonly used as palliative treatment, especially in metastases.

Radiation therapy may be useful as an adjunct to surgery. Preoperative radiation may sterilize the tumor cells rapidly and prevent its spread during surgery. It can also decrease the tumor mass to facilitate the surgery, or transforming an inoperable tumor operable in another. In other cases the radiotherapy is employed postoperatively.

Chemotherapy involves the use of drugs for the treatment of cancer. Since the drugs are distributed in the body through the circulatory system, chemotherapy is useful for those whose tumors spread makes them inaccessible to surgery or radiotherapy. There are many anticancer drugs, most of which act by interfering with DNA synthesis or function. Therefore dividing cells are more sensitive to chemotherapy.

The sensitivity of some tumors to chemotherapy is such that it is possible to cure a high percentage: this happens in uterine cancer, acute leukemias (especially in children), Hodgkin’s disease and diffuse large cell lymphomas; testicular carcinoma, ovarian carcinoma, small cell carcinoma of the lung, and most of all childhood cancers. Often these processes have spread cancer at the time of diagnosis and no other treatment option. More advanced cancers are responsive to chemotherapy and may be held for long periods, so it is frequently used as palliative treatment.

The two main problems that limit the use of chemotherapy are toxicity and resistance. The techniques that prevent or control the toxicity and reduce the risk of resistance have been refined. It is important to the establishment of early treatment, use of optimal doses of the drug, the repetition of cycles with shorter intervals if possible, always allowing patient recovery from toxic effects.
Hormone Therapy: Many cancers from tissues that are sensitive to hormone action, such as breast, prostate, endometrium and thyroid, respond to hormonal treatment. Involves the administration of various hormones or anti-hormones or termination of the corresponding stimulating hormone.

Credit to: jvillalva on Monografias

Anticarcinogenic substances in the body increases the vegetable are called polyphenols and has been shown to selectively kill or may prevent the progression of cancer cells. Thus they can be used to develop new, less toxic treatments for this disease, even cancers resistant to other treatments.The authors of this study hope to use the project results to analyze the effects of polyphenols against leukemia rhubarb. Specifically, the goal is to find the best combination of polyphenols and chemotherapeutic agents kill cells that cause the disorder, also those who have resisted previous treatments.

It is the first time explore the benefits of rhubarb growing in British gardens, a variety grown specifically in South Yorkshire. Previous investigations have focused on the rhubarb of Oriental medicine, which it previously documented benefits and is part of traditional Chinese medicine.

According to Dr. Nikki Jordan-Mahy, Center for Biomedical Research at Sheffield Hallam University, this work has shown “that the rhubarb cultivated in Britain is a potential source of pharmacological agents that can be employed to achieve creation of new anticancer drugs. “Current treatments are not effective in all cancers and the resistance is a common problem. Suffer from cancer one in three individuals in the UK, so it is very important to discover new treatments, less toxic and can overcome the problem of resistance.

Source: http://www.europapress.es/salud/noticia-hortaliza-puede-ser-base-nuevo-tratamiento-contra-cancer-20100212182311.html

In addition, oncologists have preferred to give up a first-order therapeutic tool compatible with conventional treatments and ignore the scientific literature that explains the use of mistletoe is translated into improved survival, a substantial improvement in the quality of life and greater tolerance to cytotoxic treatments.In 2001 the journal Alternative Therapies in Health and Medicine published the results of a study entitled Viscum Album in Cancer Treatment: A Systematic Investigation Epidemiology Viscum album was made for 30 years more than 35,000 residents of Heidelberg (Germany). We first chose a group of 5,000 patients who had cancer, and among them, the researchers chose more than 300 pairs of participants with the same type and stage of disease. And members of one group were given mistletoe extract in addition to conventional treatment. Well, after comparing the survival time of those who added it was found that mistletoe extract treatment lived 40% more than those who did not. “Such long-term study of high quality and scientifically rigorous is costly and difficult as this information is especially valuable-manifest David Riley, MD, Director of Alternative Therapies in Health and Medicine, the leading publication on CAM – . More and more data from basic science and clinical evidence of the efficacy of mistletoe which is the drug most common cancer in Germany. ”

Five months later the same journal published another study: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. And it was written: “Although Iscador is considered an alternative therapy for cancer is the most commonly used oncological drug in Germany.” The same authors sought to determine whether treatment with Iscador prolonged the survival time in patients with carcinoma of the colon, rectum, stomach, breast cancer, with or without distant metastases or axillary-and bronchogenic carcinoma, small cell and non-small – and explore possible synergies between Iscador treatment and psychosomatic effects. They concluded that Iscador provides a survival prolongation of clinically relevant cancer patients while improving their own psychosomatic state.

credit to: Antonio F. Wall